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Abstract
Background: Photodynamic therapy (PDT) is an effective local cancer treatment that involves
light activation of a photosensitizer, resulting in oxygen-dependent, free radical-mediated cell death.
Little is known about the comparative efficacy of PDT in treating non-small cell lung carcinoma
(NSCLC) and small cell lung carcinoma (SCLC), despite ongoing clinical trials treating lung cancers.
The present study evaluated the potential use of chlorin e6 – polyvinylpyrrolidone (Ce6-PVP) as a
multimodality photosensitizer for fluorescence detection and photodynamic therapy (PDT) on
NSCLC and SCLC xenografts.
Results: Human NSCLC (NCI-H460) and SCLC (NCI-H526) tumor cell lines were used to
establish tumor xenografts in the chick chorioallantoic membrane (CAM) model as well as in the
Balb/c nude mice. In the CAM model, Ce6-PVP was applied topically (1.0 mg/kg) and fluorescence
intensity was charted at various time points. Tumor-bearing mice were given intravenous
administration of Ce6-PVP (2.0 mg/kg) and laser irradiation at 665 nm (fluence of 150 J/cm2 and
fluence rate of 125 mW/cm2). Tumor response was evaluated at 48 h post PDT. Studies of
temporal fluorescence pharmacokinetics in CAM tumor xenografts showed that Ce6-PVP has a
selective localization and a good accuracy in demarcating NSCLC compared to SCLC from normal
surrounding CAM after 3 h post drug administration. Irradiation at 3 h drug-light interval showed
greater tumor necrosis against human NSCLC xenografts in nude mice. SCLC xenografts were
observed to express resistance to photosensitization with Ce6-PVP.
Conclusion: The formulation of Ce6-PVP is distinctly advantageous as a diagnostic and therapeutic
agent for fluorescence diagnosis and PDT of NSCLC.
Background
Photodynamic therapy (PDT) is a promising modality in
both the curative and palliative treatment against a variety
of experimental and naturally occurring human cancers
[1]. Essentially, PDT is a two-step process that begins with
the administration of photosensitizer for selective uptake
in the target tissue. The second phase involves exposure to
non-thermal light at a wavelength specific to the photo-
sensitizer at the sensitized target tissue. The activation of
the photosensitizer by light is an oxygen-dependent proc-
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ess that results in the generation of highly cytotoxic spe-
cies including singlet oxygen. The release of these reactive
molecules results in damage to both tumor cells and to
the tumor microenvironment. The significance of PDT is
that there is a degree of treatment selectivity that allows
tumor destruction with minimal involvement of healthy
tissue. This is achieved by a combination of selective accu-
mulation of photosensitizer within the tumor and by con-
trol of the light geometry and illumination parameters
[2].
Lung cancer became one of the first cancers to be consid-
ered for PDT and has been used as an adjuvant treatment
over the last 27 years [3]. Currently, PDT is used either to
treat microinvasive endobronchial non-small cell lung
carcinoma (NSCLC) or to palliate patients with com-
pletely or partially obstructing endobronchial NSCLC [4].
Despite the generally refractory nature of these type of
tumors, central type of tumors with identifiable endo-
bronchial lesions which could be easily accessed broncho-
scopically for illumination have been successfully treated
with PDT [5]. PDT can preserve lung function, limiting
surgical trauma and postoperative pain as well as used in
combination with other therapeutic modalities such as
chemotherapy [4]. Photosensitizer-induced fluorescence
detection aimed at enhancing optical contrast to improve
tumor visibility has been extensively investigated to
develop 'tumor selective' imaging methods [6,7]. The lack
of tumor selectivity, complex pharmacokinetics and the
fact that some photosensitizers may cause prolonged skin
photosensitivity, make the clinical application of fluores-
cence detection and PDT more complex [8,9]. These limi-
tations have led to the development of second-generation
photosensitizers, which usually produce shorter periods
of photosensitivity, longer activation wavelengths, higher
tumor-to-normal tissue concentration, excellent antitu-
mor effect and higher quantum yields of 1O2 [10]. Studies
showed that derivatives from chlorophylls/chlorins are
potent photosensitizers [11,12], of which mono-L-aspar-
tyl chlorin e6 (NPe6, Laserphyrin) is undergoing clinical
trials in Japan for the treatment of endobronchial lung
cancer [13].
This report investigates a new formulation that consists of
a mixture of chlorin e6 (Ce6) derived from the plant Spir-
ullina platensis and polyvinylpyrrolidone (PVP, molecular
mass = 12,000) (Fig 1). PVP is a biocompatible
hydrophilic polymer that has been used to improve disso-
lution of lipophilic drugs and to modify the biodistribu-
tion of the drug. The mixture of Ce6 and PVP has a mass
fraction ratio of 1:1. Ce6-PVP absorbs light of wavelength
above 665 nm and produces less long-term normal tissue
phototoxicity than Photofrin [14]. In our previous stud-
ies, we have demonstrated that Ce6-PVP selectively accu-
mulated in the poorly differentiated human
nasopharyngeal and human bladder carcinoma
xenografts in animal models [15-17]. We have also
reported the potential application of Ce6-PVP in photo-
dynamic therapy in one angiosarcoma patient [18]. The
present work examines the fluorescence pharmacokinetic
of Ce6-PVP in NSCLC and small cell lung carcinoma
(SCLC) xenografts on the chick chorioallantoic mem-
brane (CAM) model. We have applied the receiver operat-
ing characteristics (ROC) concept to compare the
sensitivity and specificity of fluorescence imaging on
NSCLC and SCLC using white light as the gold standard.
Molecular structure of Ce6, PVP and the absorption spectra of Ce6-PVP in PBS measured from 400 to 800 nm Figure 1
Molecular structure of Ce6, PVP and the absorption spectra of Ce6-PVP in PBS measured from 400 to 800 nm. 
Ce6-PVP has a prominent absorption at 400 nm and 665 nm.
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Photosensitizing efficacy of Ce6-PVP was also investigated
between the two histology of lung carcinoma using
murine xenografts model.
Results and discussion
Fluorescence bronchoscopy has been reported to enhance
the diagnostic accuracy and definition of the intra-epithe-
lial cancer within the bronchi [19]. This technique has
become more attractive for clinical use since more effec-
tive 2nd generations of photosensitizers have been clini-
cally implemented and tested. Newer formulations of
photosensitizers were intended to reduce common side
effects such as skin photosensitivity, nausea, vomiting and
transiently raised liver transaminase levels. Following the
above rationale, we have investigated the use of PVP in
combination with Ce6 for application in lung cancers. As
it was important to establish if cellular localization of
Ce6-PVP was also exhibited in human lung tumor, the
CAM tumor xenograft was employed here. We have dem-
onstrated that this method of examining fluorescence
uptake and retention in tissue explants on the CAM model
provides a reliable means for direct, comparative visuali-
zation  in situ of human tumors [20]. Inoculation of
human NSCLC (NCI-H460) and SCLC (NCI-H526) into
highly vascularized CAM led to the disseminated tumor
growth on the surface of the CAM (Fig 2A, C). Typical flu-
orescence intensity image of NSCLC and SCLC are illus-
trated in Fig. 2B and 2D, respectively. Intense red
Fluorescence imaging of lung cancers xenografted on the CAM model Figure 2
Fluorescence imaging of lung cancers xenografted on the CAM model. Representative of white light images of 
NSCLC and SCLC grafted on CAM before administration of photosensitizer (Fig 2A, B). Before incubation of Ce6-PVP, the 
CAM tumor xenografts were imaged under blue light illumination, to confirm that there was no autofluorescence. Tumor fluo-
rescence images at 3 h post-topical administration of 1 mg/kg of Ce6-PVP under blue light illumination (Fig 2C, D).
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fluorescence was macroscopically visible in the tumor
cells under blue light, as compared to non-malignant epi-
thelium of the CAM after 30 minutes post incubation with
Ce6-PVP. The fluorescence retention by the lung tumor
xenografts after topical administration was quantitatively
evaluated using image-processing techniques and charted
as a function of time (Fig. 3). High differential fluores-
cence intensity was observed between NSCLC xenografts
and its surrounding normal CAM tissue compared to
SCLC xenografts. The average of the red-to-blue intensity
ratio of NSCLC xenograft was higher than that of SCLC
xenograft. The fluorescence intensity elimination rate con-
stant for NSCLC, SCLC and normal CAM was calculated
to be 0.13, 0.25, and 0.38 min-1 respectively, suggesting
that Ce6-PVP is being retained longer in NSCLC than
SCLC. Normal CAM had a faster elimination rate of Ce6-
PVP.
We have applied ROC curve analysis from 0.5 to 5 h post
administration of Ce6-PVP to validate the ability of the
photosensitizer to discriminate NSCLC and SCLC from
normal CAM membrane. The area under the curve (AUC)
were then compared in order to make a fair judgment of
the effectiveness of Ce6-PVP without being constricted to
single values of sensitivity and specificity, which largely
depend on the cut-off fluorescence intensity value chosen
to distinguish normal from malignant region (Table 1).
The following is a rough guide for classifying the accuracy
of Ce6-PVP based on the AUC: 1 – 0.9 = excellent; 0.9 –
0.8 = good; 0.8 – 0.7 = fair; 0.7 – 0.6 = poor; and 0.6 – 0.5
= fail. The AUC for NSCLC were 0.52, 0.68, and 0.66, at
0.5 h, 1 h and 2 h respectively (P values were not statisti-
cally significant) indicating that shorter exposure times
resulted in lower accuracy. The greatest AUC was observed
from 3 h post drug administration onwards: i.e. 0.88, 0.94
and 0.90 at 3 h, 4 h and 5 h respectively (all P values were
statistically significant). For SCLC, the AUC were 0.52,
0.70, 0.68, 0.70, 0.74, and 0.58 at 0.5 h, 1 h, 2 h, 3 h, 4 h
and 5 h respectively (P values were not statistically signif-
icant). This result showed no improvement in fluores-
cence accuracy in demarcating SCLC from the normal
surrounding CAM. To evaluate the overall quality of fluo-
rescence intensity discrimination between NSCLC and
SCLC, a combined ROC was generated from 0.5 to 5 h
post drug administration. The sensitivity and the specifi-
city were calculated using different threshold (cut-off) val-
ues to distinguish healthy from malignant tissue (Fig 4).
For NSCLC, the highest combined sensitivity and specifi-
city were 90% and 78% (cut-off value > 4.0; likelihood
ratio = 4.03), whereas for SCLC it was 57% and 79%
respectively (cut-off value > 4.1; likelihood ratio = 2.68),
implying that fluorescence mediated Ce6-PVP had dis-
tinctly higher rate of sensitivity for the detection of dis-
seminated lesions of NSCLC than with SCLC.
To determine the efficacy of Ce6-PVP mediated PDT, nude
mice bearing NSCLC and SCLC tumors were administered
with 2.0 mg/kg of the photosensitizer. PDT was per-
formed on using light generated by a diode laser system (λ
= 665 nm) at the light dose of 150 J/cm2 and fluence rate
of 125 mW/cm2. The area of tumor necrosis was measured
by Evan's blue dye staining at 48 h post PDT. Strong het-
erogeneous staining was observed in the untreated con-
trols (Fig. 5A, B) indicating occurrence of spontaneous,
albeit limited necrosis, whereas in the PDT treated tumor,
tissue damage was clearly evident as an unstained area
(Fig 5C – F). NSCLC tumors irradiated at 3 and 6 h drug-
light interval exhibited extent of tumor necrosis of 84 ±
7% and 50 ± 4% respectively. When PDT treatment was
performed on SCLC models using the same parameter, it
was observed that irradiation at 3 h drug-light interval
resulted in 50 ± 9% of tumor necrosis while irradiation at
6 h drug-light interval resulted in 26 ± 8% tumor necrosis.
Thus, we conclude that SCLC were only moderately sensi-
tive to Ce6-PVP mediated PDT.
Almost all PDT studies were concerned with NSCLC due
to the referral patterns in the clinics [5]. Although PDT has
also been shown to be effective in the clinical treatment of
SCLC [21], little preclinical data exist comparing the effi-
Fluorescence kinetics of Ce6-PVP on NSCLC (▲ ) and SCLC  (■ ) xenografted on CAM examined up to 24 h post topical  drug administration Figure 3
Fluorescence kinetics of Ce6-PVP on NSCLC (▲ ) 
and SCLC (■ ) xenografted on CAM examined up to 
24 h post topical drug administration. Values are 
expressed as red-to-blue intensity ratio of fluorescence 
images post administration of drug normalized with images 
before drug administration. For tumor, each point represents 
a mean of 5 eggs whereas for normal (● ), each point repre-
sents a mean of 10 eggs. Bars = standard error of the mean. 
Non-linear regression analysis demonstrated that all the 
curves were statistically different with each other. The elimi-
nation rate constant for NSCLC, SCLC and normal CAM 
was in the following order: NSCLC < SCLC < normal CAM.
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cacy or tendency for resistance toward photosensitization
between these two tumor histologies. In this study, we
observed a certain degree of resistance to PDT in SCLC
xenografts that could be related to faster elimination rate
of Ce6-PVP, which resulted in lower cellular accumula-
tion of the photosensitizer. There are already a variety of
molecular markers that have been implicated in the
pathogenesis of SCLC [22] thus making it difficult to
hypothesize the molecular basis of acquired resistance
towards photosensitization in our experiments. Gener-
ally, in lung cancer four types of multidrug resistance have
been identified, i.e., classical multidrug resistance (MDR),
non-P-glycoprotein MDR (also called MRP), atypical
MDR (mediated through altered expression of topoi-
somerases II) and lung resistance-related protein [23].
Previous evidence indicates that SCLC cell lines and
tumors express multidrug resistance-associated protein,
i.e. MRP1, ATP binding cassette [ABC]C1 [24] and ABCG2
(ATP-binding cassette protein for breast cancer resistance
protein) [25]. Hence, one plausible reason to explain the
lack of activity of Ce6-PVP in SCLC is the possible exist-
ence of ABC transporters of chlorin-based (tetrapyrrole)
photosensitizers in this tumor histology. The importance
of human ABCG2 in the transport of tetrapyrrole structure
has been implicated [26]. It was reported that cancer cell
lines that expresses ABCG2 was found to efflux some of
the chlorophyll based photosensitizers and thus may con-
fer resistance to this treatment modality [27,28]. It has
been suggested that by inhibiting ABCG2 transport using
tyrosine kinase inhibitors (e.g. Gleevec), it is likely to be a
more successful approach to enhancing clinical PDT [29].
Conclusion
Photosensitization with Ce6-PVP for 3 hours of exposure
time appeared to be most effective in detecting NSCLC in
CAM model. Furthermore, PDT at 3 h drug-light interval
resulted in a better tumor necrosis in NSCLC xenograft
model. SCLC xenografts were found to manifest a certain
degree of resistance to photosensitization with Ce6-PVP.
Despite the limited activity of Ce6-PVP in the SCLC
xenografts, it is conceivable that the combined modality
of fluorescence imaging and targeted photodynamic ther-
apy using Ce6-PVP may still have a potential role in SCLC.
This warrants for additional studies on the molecular
mechanisms of photosensitization resistance in SCLC to
overcome this important clinical problem.
Table 1: A comparison of areas under the ROC curves between NSCLC and SCLC at various time post drug administration.
Time post Ce6 – PVP 
administration, h
NSCLC SCLC
Area under the ROC curve P value Area under the ROC curve P value
0.5 0.52 0.9024 0.52 0.9025
1 0.68 0.2704 0.70 0.2207
2 0.66 0.3272 0.68 0.2704
3 0.88 0.0200* 0.70 0.2207
4 0.94 0.0071* 0.74 0.1417
5 0.90 0.0143* 0.58 0.6242
An area of 1 represents a perfect discrimination of tumor from normal tissue; an area of 0.5 represents no discrimination between normal and 
abnormal. The P value indicates whether the area under the ROC is significantly different from 0.5. *If the P value is < 0.05, the area under the ROC 
curve is significantly different (see description of statistical analysis). For tumors, each point represents a mean of 5 eggs whereas for normal, each 
point represents a mean of 10 eggs.
Receiver operating characteristic curves illustrating the abil- ity of Ce6-PVP to separate NSCLC (solid line) and SCLC  (dotted line) from normal chorioallantoic membrane in the  CAM model Figure 4
Receiver operating characteristic curves illustrating 
the ability of Ce6-PVP to separate NSCLC (solid line) 
and SCLC (dotted line) from normal chorioallantoic 
membrane in the CAM model. The ROC curve of two 
indistinguishable populations (i.e. abnormal versus normal 
region), represented by the 45-degree line (area under the 
ROC curve = 0.5), is included for comparison. Area under 
the ROC curve was 082 ± 0.04 (p < 0.0001) and 0.70 ± 0.05 
(p = 0.0009118) for NSCLC and SCLC respectively.
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Methods
Photosensitizer: Ce6-PVP
Ce6-PVP was manufactured by ORPEGEN Pharma
GmbH, Heidelberg, Germany. It is a co-lyophilisate of
chlorin e6 (Ce6) and polyvinypyrrolidone (PVP, molecu-
lar mass ≈ 12,000) in a 1:1 mass ratio. A working concen-
tration of 0.03 mM of Ce6-PVP was prepared using
phosphate buffered saline to measure the absorption
spectra. 1 ml of the solution was placed in a cuvette and
the absorbance was measured from 300 – 800 nm.
Absorption spectra were recorded on a spectrofluoropho-
tometer RF-5301 PC (Shimadzu, Japan).
Cell culture
The NCI-H460 cell line originates from human carcinoma
of the large cell lung cancer. NCI-H526 cell lines originate
from human carcinoma of the lung from the variant small
cell lung cancer were obtained from the American Type
Culture Collection, USA. NCI-H460 cells were cultured as
a monolayer whereas NCI-H526 cells were cultured in
suspension in RPMI-1640 medium supplemented with
10% fetal bovine serum, 1% non-essential amino acids
(Gibco, USA), 1% sodium pyruvate (Gibco, USA), 100
units/ml penicillin/streptomycin (Gibco, USA) and incu-
bated at 37°C, 95% humidity and 5% CO2. Before inocu-
lation, the monolayer cells were washed with phosphate-
A morphologic study of NSCLC and SCLC tumor damage efficiency using the method of vital staining with Evans blue at 48 h  post Ce6-PVP mediated PDT Figure 5
A morphologic study of NSCLC and SCLC tumor damage efficiency using the method of vital staining with 
Evans blue at 48 h post Ce6-PVP mediated PDT. Strong homogeneous staining was observed in the untreated controls 
(Fig. 5A, B), whereas in the treated tumor at 3 h drug-light interval (DLI) (Fig 5C, D) and at 6 h DLI (Fig 5E, F). Tissues damage 
was clearly distinguishable as an unstained area in the the tumor. Drug dose: 2.0 mg/kg; light dose: 150 J/cm2; 125 mW/cm2. 
Each data point is an average of at least 5 animals, Bars = standard error of the mean. *The mean difference is significant at the 
0.05 level compared to the NSCLC group.
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buffered saline, trypsinized, and counted using a haema-
cytometer. Suspension cells were directly counted using a
haemacytometer without trypsinization.
CAM tumor xenograft
Fertilized chicken eggs were incubated at 37°C in a
humidified atmosphere inside a hatching incubator
equipped with an automatic rotator (Octagon 20, Brinsea,
Somerset, UK). At embryo age (EA) 7, a window of about
1.5 cm was opened in the eggshell to detach the shell
membrane from the developing CAM. Then, the window
was sealed with sterilized parafilm to avoid contamina-
tion and the eggs were returned to the static incubator for
further incubation until the day of experiments. On EA 9,
approximately 5 × 106 NCI-H460 and NCI-H526 cells
were inoculated on the CAM. The window of the eggs
were resealed with sterile parafilm and returned to the
static incubator. Grafted cells were allowed to grow on the
CAM for up to 5 days. On EA 14, Ce6-PVP was dissolved
in 0.9% sodium chloride (B. Braun Medical Inc, USA) to
constitute a stock solution of 1 mg/mL. The stock solution
was further diluted to obtain a volume of 80 µL contain-
ing a dose of 1 mg/kg body weight of the chick's embryo.
The photosensitizer was applied on the entire surface of
the CAM and left to incubate for 30 min. The window was
resealed to avoid evaporation of the drug solution from
the CAM. After 30 min incubation, imaging was per-
formed at 0.5, 1, 2, 3, 4, 5, 6, and 24 h post drug admin-
istration. All procedures involving preparation and
administration of the photosensitizer were conducted
under low ambient lighting.
Fluorescence imaging
Fluorescence images were performed using the Karl Storz
D-light fluorescence endoscopy system (Karl Storz, Tut-
tlingen, Germany). This D-light system consisted of xenon
short arc lamp, filtered by a band pass filter (370 – 450
nm) to excite Ce6-PVP and a sensitive colour CCD video
camera connected to a modified endoscope integrated
with long pass filter (cut-off wavelength at 560 nm). The
red channel registered the photosensitizer's fluorescence
and the blue channel captured the diffusely back-scattered
excitation light. The intensities of the red and blue chan-
nels of the fluorescence images were quantified using the
software MicroImage (Olympus Optical Co. (Europa),
Germany). The red-to-blue intensity ratio of the fluores-
cence endoscopic image algorithm was found to be effec-
tive in separating benign tissue from dysplasia, and
carcinoma in situ/squamous cell carcinoma from dyspla-
sia [30]. By applying the red-to-blue intensity ratio as a
diagnostic algorithm, the intensities of the red fluores-
cence of Ce6-PVP are determined as a function of time.
Such algorithm is independent of the geometries of exci-
tation/collection of signals and the power of excitation
during the fluorescence imaging process [31].
Statistical analysis of fluorescence image
To statistically evaluate the temporal fluorescence of Ce6-
PVP, logistic regression and receiver operating characteris-
tics (ROC) curve [32] was determined using the GraphPad
software for Windows (GraphPad, San Diego, CA). The
elimination rate constant of Ce6-PVP was calculated by a
method fitting the data to a one-phase exponential decay
equation. The validity of fitted curve was verified with the
test of runs (F test) in each case. Area under the curve
(AUC), P value, and cut-off point were obtained from the
ROC curve. The area under the ROC curve measures accu-
racy of the fluorescence images. The accuracy of the ROC
curve analysis is based on how well the fluorescence
images discriminates the tumor region from the normal
CAM, as defined by white light imaging. The closer the
curve follows the left border and then the top border of
the ROC space, the more accurate the test. The closer the
curve comes to the 45-degree diagonal of the ROC space,
the less accurate the test. In addition, likelihood ratios
(where the likelihood ratio is defined as the ratio of the
probability of the fluorescence signal for tumor to the
probability of the fluorescence signal for normal region)
were calculated to help determine the 'best' cut-off point
to compare sensitivity and specificity between NSCLC and
SCLC.
PDT treatment on murine xenograft model
Male Balb/c athymic (nu+/nu+) (ARC, WA, Australia)
mice were used for tumor xenografting at the age of 8–10
weeks. Approximately 3.0 × 106  NCI-H460 and NCI-
H526 cells suspended in 150 µl of Hank's buffered saline
solution were injected subcutaneously into both lower
flanks of the mice. The animals were used for experiments
when the tumors measured a surface diameter around 7 –
10 mm. A dose of 2.0 mg/kg of the photosensitizer was
administered intravenously through the tail vein. The
mice were anaesthetized with 50 µl cocktail of ketamine
hydrochloride (50 mg/ml, Trittau, Germany) and valium
(1:1 vol/vol) through intraperitoneal injection. A diode
laser (Ceralas PDT 665, Biolitec) emitting at a wavelength
of 665 ± 3 nm was used for irradiation. The peak power
output was calibrated to 1.65 W at the fiber tip before
commencement of irradiation. The laser energy with a
total fluence of 150 J/cm2 was delivered to a 1.0 cm2 circu-
lar spot on the surface of the tumor via a silica fiber frontal
light distributor (FD model, Medlight, Switzerland). Flu-
ence rate of 125 mW/cm2 was measured using a power
meter (LaserCheck, Coherent, USA). PDT treatment was
performed at 3 and 6 h drug-light interval on one tumor
while the contralateral tumor that was not irradiated
served as controls. All procedures were approved by the
national experimental animal welfare institution (Institu-
tional Animal Care and Use Committee, SingHealth, Sin-
gapore), in accordance with international standards.BMC Pharmacology 2007, 7:15 http://www.biomedcentral.com/1471-2210/7/15
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Macroscopic assessment of tumor response post PDT
At 48 h post PDT, 1% Evans Blue (Merck, Germany) in
PBS was injected intraperitoneally at a volume of 0.4 mL
in mice for examination of viable or necrotic tissues at
post PDT. Six hours later, animals were sacrificed and the
tumors were excised. Around 2–3 mm thick cross-section
slices were cut in a plane parallel to the direction of inci-
dent light and imaged under a stereoscopic microscope
(Stemi 2000C, Zeiss, Germany). The unstained area was
attributed to tissue necrosis, whereas the blue stained area
indicated viable tissue. Digital images were all analyzed
using NIH Image v1.62 software. Each image captured
had the same calibration values to allow uniformity in the
processing of the images. The tumor was outlined using
the freehand drawing tool to measure the total tumor
area. Similarly the necrotic area of the tumor was meas-
ured. The percentage of necrosis was calculated as the
necrotic area divided by the total tumor area multiplied by
100. Statistical analysis (Student's t test) was used for mul-
tiple comparisons. The criterion for statistical significance
was set at the 0.05 level.
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